Insights & Resources
Expert guidance on compounding, wellness and personalized medicine.
FDA Regulation
What the Recent Peptide Nomination Withdrawals Mean
The FDA's April 2026 decision to lift BPC-157, TB-500, and MOTS-c from its 'do not compound' list has reopened the conversation for providers, but a regulatory gray zone remains ahead of the July 2...
